Related Experiment Videos
[Vagus nerve stimulation for partial seizures]
M Neufeld1, G Quaknine, A Korczyn
1Neurology Dept., Sourasky-Tel Aviv Medical Center.
Harefuah
|July 1, 1995
Summary
Electrical vagus nerve stimulation (VNS) shows promise for controlling refractory epilepsy. Studies indicate VNS can reduce seizure frequency by 30-50% in about half of patients with minimal complications.
Area of Science:
- Neurology
- Neurosurgery
- Epileptology
Background:
- Cerebellar and thalamic stimulation are established methods for epilepsy control.
- Electrical vagus nerve stimulation (VNS) has emerged as a novel therapeutic approach.
- VNS has demonstrated efficacy in animal models for seizure management.
Purpose of the Study:
- To evaluate the efficacy and safety of transcutaneous VNS in patients with refractory partial seizures.
- To report the initial human use of a programmable VNS device for epilepsy treatment.
- To assess seizure reduction and complication rates associated with VNS.
Main Methods:
- Development of a transcutaneous programmable pulse generator and electrode lead for human VNS.
- Conducted 2 pilot studies and a multicenter, prospective, randomized, parallel, double-blind study.
- Follow-up duration ranged from 3 to 22 months.
Main Results:
- Approximately 50% of patients experienced a 30-50% reduction in seizure frequency.
- No significant complications were reported with the VNS implant.
- Common side-effects included hoarseness, coughing, and throat pain.
Conclusions:
- Transcutaneous VNS is a potentially effective and safe adjunctive therapy for refractory partial seizures.
- Further extensive clinical trials are necessary to confirm long-term efficacy and safety.
- This study reports the first VNS cases in Israel, contributing to global research on epilepsy treatment.